Stock Price: As of November 15, 2023, Akebia Therapeutics’ stock price is $1.03, with a 52-week range between $0.24 and $1.84.
Market Cap: The company’s market capitalization stands at $190.22 million.
Revenue: In 2022, Akebia’s revenue was $292.48 million, showing a significant increase of 38.19% compared to the previous year’s $211.65 million.
Net Income: Despite challenges, the company’s net losses decreased to -$94.23 million, which is 66.59% less than in 2021.
Analyst Consensus
Rating: According to 2 analysts, the average rating for AKBA stock is a resounding “Strong Buy.”
Price Target: The 12-month stock price forecast is $3.88, implying an impressive increase of 276.70% from the latest price12.
Recent Business Highlights
Akebia Therapeutics reported its third-quarter 2023 financial results and highlighted recent business achievements.
The company’s drug candidate Vadadustat received FDA acceptance for resubmission to the New Drug Application (NDA) for the treatment of anemia due to chronic kidney disease.
Vadadustat has also been approved in 36 countries, including Australia and Taiwan.
Akebia strengthened its cash position, positioning itself for potential Vadadustat launch1.
Conclusion
Akebia Therapeutics, with its focus on kidney disease treatments, shows promise. However, as with any investment, consider risks and conduct thorough research before making decisions.